Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the CRUSADE initiative

BACKGROUND: Glycoprotein (GP) IIb/IIIa inhibitors can improve outcomes in patients with non–ST-segment elevation acute coronary syndromes (NSTE ACS) but raise the risk of bleeding, particularly if dosed in excess. The impact of GP IIb/IIIa dosing feedback on safety and major bleeding is unknown. MET...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mudrick, Daniel W., Chen, Anita Y., Roe, Matthew T., Newby, L. Kristin, Gibler, W. Brian, Ohman, E. Magnus, Peterson, Eric D., Alexander, Karen P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3058758/
https://ncbi.nlm.nih.gov/pubmed/21146660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2010.08.008
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge